The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams

Phase 4

Completed

• Conditions: Neuroscience of Dreaming, Healthy
• Interventions: Other: Placebo; Drug: Naltrexone

• Registration Number: NCT02792140
• Lead Sponsor: University of Bern

Brief Summary

In this study, the investigators pose the question which influence the opioid circuit has on positive valent situations in dreams.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03
• Study First Submitted: 2016-06-02
• Study First Submitted QC: 2016-06-02
• Study First Posted: 2016-06-07
• Primary Completion: 2016-11
• Study Completion: 2016-11
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-04
• Last Update Posted: 2017-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 32

Inclusion Criteria

• Written informed consent
• Healthiness
• Good capacity of remembering dreams
• No opiate consumption

Read More

Exclusion Criteria

• Simultaneous participation in other studies
• Addictive disorder
• Abnormal liver function
• Abnormal kidney function
• Hypersensitivity to active ingredient or pharmaceutical additives
• Hereditary galactose intolerance
• Lactase deficiency
• Glucose-galactose malabsorption
• Intake of opioid medication

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	daily administration of Placebo, reporting of dreams
Naltrexone	Naltrexone	daily administration of 50mg Naltrexone, reporting of dreams

Primary Outcome Measures

Name	Time	Method
VAS-difference concerning the emotional valence of dreams	7 days per condition (Naltrexone, Placebo), intermitted by 14 days of washout	Difference between the mean values of emotional valence of dreams reported in the conditions (Naltrexone, Placebo), as captured in VAS \[visual analog scales\] for every dream

Secondary Outcome Measures

Name	Time	Method
Semiquantitative score of emotional valence of dreams	7 days per condition (Baseline, Naltrexone, Placebo), intermitted by 14 days of washout	Based on computational linguistic analysis of the dreams
Qualitative score of emotional valence of dreams	7 days per condition (Baseline, Naltrexone, Placebo), intermitted by 14 days of washout	Based on lexical coding of the dreams

Trial Locations

Locations (1)

University of Bern; 🇨🇭 Bern, Switzerland